Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2006, Article ID 26986, 8 pages
http://dx.doi.org/10.1155/SRCM/2006/26986
Clinical Study

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)

A. López-Pousa,1 J. Martín,2 J. Montalar,3 R. de las Peñas,4 J. García del Muro,5 J. Cruz,6 J. Maurel,7 P. Escudero,8 A. Casado,9 J. M. Buesa,10 and the Spanish Group for Research on Sarcomas (GEIS)1

1Medical Oncology Department, Hospital Sant Pau, Barcelona 08025, Spain
2Medical Oncology Department, Hospital Son Dureta, Palma de Mallorca 07014, Spain
3Medical Oncology Department, Hospital Clínico La Fe, Valencia 46009, Spain
4Medical Oncology Department, Hospital Provincial, Castellón 12002, Spain
5Medical Oncology Department, Instituto Catalán de Oncología, Barcelona 08907, Spain
6Medical Oncology Department, Hospital Universitario de Canarias, Tenerife 38320, Spain
7Medical Oncology Department, Hospital Clínic, Barcelona 08036, Spain
8Medical Oncology Department, Hospital Clínico, Zaragoza 50009, Spain
9Medical Oncology Department, Hospital Clínico San Carlos, Madrid 28040, Spain
10Medical Oncology Department, Hospital Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo 33006, Spain

Received 27 December 2005; Revised 22 May 2006; Accepted 6 June 2006

Copyright © 2006 A. López-Pousa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M F Brennan, E S Casper, and L B Harrison, “Soft tissue sarcoma,” in Cancer, Principles and Practice of Oncology, V T DeVita, S Hellman, and S A Rosenberg, Eds., pp. 1738–1788, Lippincott-Raven, New York, NY, 5th edition, 1997. View at Google Scholar
  2. A Santoro, T Tursz, H Mouridsen et al., “Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1537–1545, 1995. View at Google Scholar
  3. J H Edmonson, L M Ryan, R H Blum et al., “Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1269–1275, 1993. View at Google Scholar
  4. K Antman, J Crowley, S P Balcerzak et al., “An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1276–1285, 1993. View at Google Scholar
  5. A Le Cesne, I Judson, D Crowther et al., “Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus infosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 18, no. 14, pp. 2676–2684, 2000. View at Google Scholar
  6. A Le Cesne, E Antoine, M Spielmann et al., “High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1600–1608, 1995. View at Google Scholar
  7. R Palumbo, S Palmeri, M Antimi et al., “Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas,” Annals of Oncology, vol. 8, no. 11, pp. 1159–1162, 1997. View at Publisher · View at Google Scholar
  8. S R Patel, S Vadhan-Raj, M A Burgess et al., “Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 21, no. 3, pp. 317–321, 1998. View at Publisher · View at Google Scholar
  9. T De Pas, F De Braud, L Orlando et al., “High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?” Annals of Oncology, vol. 9, no. 8, pp. 917–919, 1998. View at Publisher · View at Google Scholar
  10. R Reichardt, J Tilgner, P Hohenberger, and B Dörken, “Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1438–1443, 1998. View at Google Scholar
  11. R Palumbo and S Toma, “Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: a phase I study,” European Journal of Cancer Part A: General Topics, vol. 31, no. 9, pp. 1552–1553, 1995. View at Google Scholar
  12. J M Buesa, A López-Pousa, J Martín et al., “Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS),” Annals of Oncology, vol. 9, no. 8, pp. 871–876, 1998. View at Publisher · View at Google Scholar
  13. A B Miller, B Hoogstraten, M Staquet, and A Winkler, “Reporting results of cancer treatment,” Cancer, vol. 47, no. 1, pp. 207–214, 1981. View at Publisher · View at Google Scholar
  14. E A Gehan, “The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent,” Journal of Chronic Diseases, vol. 13, pp. 346–353, 1961. View at Publisher · View at Google Scholar
  15. S Leyvraz, M Bacchi, T Cerny et al., “Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas,” Annals of Oncology, vol. 9, no. 8, pp. 877–884, 1998. View at Publisher · View at Google Scholar
  16. F P Worden, J MG Taylor, J S Biermann et al., “Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 105–112, 2005. View at Publisher · View at Google Scholar
  17. S Frustaci, A Buonadonna, E Galligioni et al., “Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 1418–1426, 1997. View at Google Scholar
  18. R Palumbo, C Neumaier, M Cosso et al., “Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study,” European Journal of Cancer, vol. 35, no. 1, pp. 66–72, 1999. View at Publisher · View at Google Scholar
  19. J Maurel, J Fra, A López-Pousa et al., “Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a phase II trial by the Spanish Group for Research on Sarcomas (GEIS),” Cancer, vol. 100, no. 7, pp. 1498–1506, 2004. View at Publisher · View at Google Scholar
  20. T De Pas, G Curigliano, G Masci et al., “Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas,” Annals of Oncology, vol. 13, no. 1, pp. 161–166, 2002. View at Publisher · View at Google Scholar
  21. J Maurel, J M Buesa, A López-Pousa et al., “Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias. A study of the Spanish Group for Research on Sarcomas (GEIS),” Journal of Surgical Oncology, vol. 88, no. 1, pp. 44–49, 2004. View at Publisher · View at Google Scholar
  22. M Di Maio, C Gridelli, C Gallo et al., “Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials,” Lancet Oncology, vol. 6, no. 9, pp. 669–677, 2005. View at Publisher · View at Google Scholar
  23. H Gurney, “I don't underdose my patientsdo I?” Lancet Oncology, vol. 6, no. 9, pp. 637–638, 2005. View at Publisher · View at Google Scholar